What is the share price of Suraksha Diagnostic Ltd (SURAKSHA) today?
The share price of SURAKSHA as on 23rd March 2026 is ₹254.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Suraksha Diagnostic Ltd (SURAKSHA) share?
The past returns of Suraksha Diagnostic Ltd (SURAKSHA) share are- Past 1 week: N/A%
- Past 1 month: -5.35%
- Past 3 months: -4.63%
- Past 6 months: -18.73%
- Past 1 year: -9.77%
- Past 3 years: N/A%
- Past 5 years: -37.62%
What are the peers or stocks similar to Suraksha Diagnostic Ltd (SURAKSHA)?
The peers or stocks similar to Suraksha Diagnostic Ltd (SURAKSHA) include:What is the market cap of Suraksha Diagnostic Ltd (SURAKSHA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Suraksha Diagnostic Ltd (SURAKSHA) is ₹1319.73 Cr as of 23rd March 2026.What is the 52 week high and low of Suraksha Diagnostic Ltd (SURAKSHA) share?
The 52-week high of Suraksha Diagnostic Ltd (SURAKSHA) is ₹352.50 and the 52-week low is ₹240.What is the PE and PB ratio of Suraksha Diagnostic Ltd (SURAKSHA) stock?
The P/E (price-to-earnings) ratio of Suraksha Diagnostic Ltd (SURAKSHA) is 41.45. The P/B (price-to-book) ratio is 6.28.Which sector does Suraksha Diagnostic Ltd (SURAKSHA) belong to?
Suraksha Diagnostic Ltd (SURAKSHA) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.How to buy Suraksha Diagnostic Ltd (SURAKSHA) shares?
You can directly buy Suraksha Diagnostic Ltd (SURAKSHA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Suraksha Diagnostic Ltd
SURAKSHA Share Price
NSE₹254.402.27% (-5.90)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SURAKSHA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SURAKSHA Performance & Key Metrics
SURAKSHA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 39.64 | 6.28 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.10 | 5.54 | 0.61% |
0%
Analysts have suggested that investors can buy this stock
from 1 analyst
Price Upside
Earnings Growth
Rev. Growth
SURAKSHA Company Profile
Suraksha Diagnostic Ltd operates diagnostic centers offering comprehensive pathology and radiology services, including imaging and medical consultations.
APOLLOHOSP
PE Ratio
72.12
72.12
1Y Return
13.75%
13.75%
Buy Reco %
86.21
86.21
MAXHEALTH
PE Ratio
86.21
86.21
1Y Return
15.06%
15.06%
Buy Reco %
81.82
81.82
FORTIS
PE Ratio
79.80
79.80
1Y Return
31.04%
31.04%
Buy Reco %
82.35
82.35
PE Ratio
42.37
42.37
1Y Return
1.99%
1.99%
Buy Reco %
80.00
80.00
ASTERDM
PE Ratio
6.12
6.12
1Y Return
44.64%
44.64%
Buy Reco %
100.00
100.00
SURAKSHA Sentiment Analysis
SURAKSHA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SURAKSHA Stock Summary · November 2025
Suraksha Diagnostics reported a cautious yet optimistic outlook for future growth, driven by a strategic expansion of its network and the launch of a genomics division. Despite facing operational challenges due to adverse weather and the initial impact of new centers on profitability, management remains confident in achieving a projected 15% revenue growth for FY26. The company is focused on enhancing relationships with local healthcare providers to boost service adoption and customer loyalty, while also addressing rising operational costs through tighter cost controls. As new centers mature, expectations for improved margins and increased revenue from innovative testing services are anticipated, positioning the company for long-term success in an evolving market.
SURAKSHA Stock Growth Drivers
SURAKSHA Stock Growth Drivers
8Network Expansion
Suraksha Diagnostic Limited has successfully expanded its network by adding three new centers during Q2
Launch of Suraksha Genomics
The company has launched Suraksha Genomics, which offers advanced genetic and molecular testing services, marking
SURAKSHA Stock Challenges
SURAKSHA Stock Challenges
6Decline in Profitability
The company reported a decrease in Profit After Tax (PAT) for Q2 FY26, falling to
Operational Disruptions Due to Weather
Severe weather events, particularly torrential rainfall and flooding, significantly disrupted business operations. During a four-day
SURAKSHA Forecast
SURAKSHA Forecasts
Price
Revenue
Earnings
SURAKSHA Share Price Forecast
SURAKSHA Share Price Forecast
2026
Current
₹260.30
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹260.30
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
SURAKSHA Company Revenue Forecast
SURAKSHA Company Revenue Forecast
2025
Current
₹255.94
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
2025
Current
₹255.94
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
SURAKSHA Stock EPS (Earnings Per Share) Forecast
SURAKSHA Stock EPS (Earnings Per Share) Forecast
2025
Current
₹10.49
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹10.49
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
SURAKSHA
SURAKSHA
Income
Balance Sheet
Cash Flow
Quarterly Normal View
SURAKSHA Income Statement
SURAKSHA Income Statement
Quarterly Normal View
| Quarter | sep 2023 | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 60.60 | 52.67 | 56.17 | 61.85 | 68.07 | 60.11 | 65.91 | 73.49 | 79.58 | 78.31 | ||||||||||
Operating & Other expenses | 39.21 | 36.51 | 36.50 | 40.13 | 43.56 | 41.26 | 45.91 | 48.84 | 54.61 | 54.53 | ||||||||||
EBITDA | 21.39 | 16.16 | 19.67 | 21.72 | 24.51 | 18.85 | 20.00 | 24.65 | 24.97 | 23.78 | ||||||||||
| Depreciation/Amortization | 7.95 | 7.92 | 8.36 | 8.99 | 8.75 | 8.83 | 8.73 | 9.48 | 10.14 | 10.56 | ||||||||||
| PBIT | 13.44 | 8.24 | 11.31 | 12.73 | 15.76 | 10.02 | 11.27 | 15.17 | 14.83 | 13.22 | ||||||||||
| Interest & Other Items | 2.48 | 2.03 | 2.08 | 2.22 | 2.13 | 1.98 | 2.06 | 2.70 | 2.78 | 3.16 | ||||||||||
| PBT | 10.96 | 6.21 | 9.23 | 10.51 | 13.63 | 8.04 | 9.21 | 12.47 | 12.05 | 10.06 | ||||||||||
| Taxes & Other Items | 2.56 | 1.56 | 2.71 | 2.57 | 3.29 | 1.89 | 1.82 | 3.08 | 3.06 | 2.54 | ||||||||||
| Net Income | 8.40 | 4.65 | 6.52 | 7.94 | 10.34 | 6.15 | 7.39 | 9.39 | 8.99 | 7.52 | ||||||||||
| EPS | 2.44 | 0.87 | 1.22 | 1.49 | 1.94 | 1.18 | 1.42 | 1.80 | 1.73 | 1.44 |
SURAKSHA Company Updates
FY 2026FY 2026
Investor Presentation
Feb 5PDF
Nov 10PDF
Aug 9PDF
SURAKSHA Stock Peers
SURAKSHA Past Performance & Peer Comparison
SURAKSHA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareHospitals & Diagnostic Centres
Compare valuation on Screener
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Suraksha Diagnostic Ltd | 41.45 | 6.28 | — |
| Apollo Hospitals Enterprise Ltd | 72.12 | 9.40 | 0.17% |
| Max Healthcare Institute Ltd | 86.21 | 9.89 | 0.16% |
| Fortis Healthcare Ltd | 79.80 | 6.74 | 0.12% |
SURAKSHA Stock Price Comparison
Compare SURAKSHA with any stock or ETFCompare SURAKSHA with any stock or ETF
SURAKSHA
SURAKSHA Holdings
SURAKSHA Shareholdings
SURAKSHA Promoter Holdings Trend
SURAKSHA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SURAKSHA Institutional Holdings Trend
SURAKSHA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SURAKSHA Shareholding Pattern
SURAKSHA Shareholding Pattern
SURAKSHA Shareholding History
SURAKSHA Shareholding History
Foreign Institutions
Mutual Funds Invested in SURAKSHA
Mutual Funds Invested in SURAKSHA
No mutual funds holding trends are available
Top 5 Mutual Funds holding Suraksha Diagnostic Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9075% | Percentage of the fund’s portfolio invested in the stock 0.60% | Change in the portfolio weight of the stock over the last 3 months -0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 56/86 (-3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5897% | Percentage of the fund’s portfolio invested in the stock 1.20% | Change in the portfolio weight of the stock over the last 3 months 0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 29/75 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0005% | Percentage of the fund’s portfolio invested in the stock 0.04% | Change in the portfolio weight of the stock over the last 3 months -0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 103/123 (-3) |
Compare 3-month MF holding change on Screener
smallcases containing SURAKSHA stock
smallcases containing SURAKSHA stock
Looks like this stock is not in any smallcase yet.
SURAKSHA Events
SURAKSHA Events
SURAKSHA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SURAKSHA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SURAKSHA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SURAKSHA has not given any dividends in last 5 years
SURAKSHA Dividends
SURAKSHA Dividends
Hmm, looks like data is unavailable here. Please come back after some timeSURAKSHA Stock News & Opinions
SURAKSHA Stock News & Opinions
Articles & Videos
Live Market Update
Benchmarks trade in negative terrain; media shares drop
The key equity benchmarks traded with substantial losses in the mid-afternoon trade adopted a risk-off approach amid escalating geopolitical tensions following the US-Israel attacks on Iran. Traders are closely monitoring crude oil and metal prices. The Nifty slipped below the 24,800 level, reflecting weak market sentiment. Media shares declined after advancing in the past trading session. At 14:25 IST, the barometer index, the S&P BSE Sensex tanked 1,351.91 points or 1.66% to 79,911.22. The Nifty 50 index tumbled 420.15 points or 1.67% to 24,762.05. In the broader market, the BSE 150 MidCap Index declined 1.79% and the BSE 250 SmallCap Index slipped 2.32%. The market breadth was negative. On the BSE, 612 shares rose and 3,688 shares fell. A total of 167 shares were unchanged. The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, rallied 27.23% to 17.44. Buzzing Index: The Nifty Media index fell 2.22% to 1,386.25. The index advanced 0.60% in the past trading session. Hathway Cable & Datacom (down 5.13%), Zee Entertainment Enterprises (down 4.38%), D B Corp (down 3.89%), Nazara Technologies (down 3.53%), Sun TV Network (down 3.4%), Network 18 Media & Investments (down 2.55%), Saregama India (down 2.39%), Tips Music (down 2.27%), PVR Inox (down 1.79%) declined. US-Iran Conflict: The United States and Israel have launched major coordinated military strikes on Iran, marking a significant escalation in long-running Middle East tensions. On 1 March 2026, Iran launches missile and drone strikes on U.S. bases across six Middle Eastern countries amid escalating military tensions. Iran's Supreme Leader Ayatollah Ali Khamenei was reportedly killed in the attacks, escalating tensions further. Following his death, Iran appointed Ayatollah Alireza Arafi to its interim leadership council, which will assume charge of the country's affairs. Numbers to Track: The yield on India's 10-year benchmark federal paper rose 0.54% to 6.697 compared with the previous session close of 6.661. In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 91.4700 compared with its close of 91.0800 during the previous trading session. MCX Gold futures for 2 April 2026 settlement gained 4.23% to Rs 168,950. The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.83% to 98.42. The United States 10-year bond yield jumped 0.18% to 3.965. In the commodities market, Brent crude for May 2026 settlement surged $6.21 or 8.52% to $79.08 a barrel. amid heightened geopolitical tensions. According to media reports, Saudi Arabia's state-owned oil major Aramco temporarily shut down its Ras Tanura refinery on Monday as a precautionary measure after an Iranian drone strike reportedly sparked a fire at the facility. Stocks in Spotlight: Suraksha Diagnostic fell 2.06% after its group chief financial officer (CFO) and key managerial personnel (KMP), K S Ravindra, has tendered his resignation due to personal reasons. The company said Ravindra will step down from his role on or before 31 May, 2026, close of business hours.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Spotlight
Suraksha Diagnostic slides as CFO K S Ravindra resigns
The company said Ravindra will step down from his role on or before 31 May, 2026, close of business hours. In his resignation letter, Ravindra confirmed that there are no material reasons for his decision other than those stated. The diagnostics services provider clarified that disclosures relating to appointment of director and relationship between directors are not applicable in this case, as the resignation pertains solely to the CFO position. The company did not immediately announce a successor. Suraksha Diagnostic offers integrated pathology and radiology testing, along with medical consultancy services. The company had reported a 21% rise in consolidated net profit to Rs 7.24 crore on a 30.5% increase in total revenue from operations to Rs 77.69 crore in Q3 FY26 as compared with Q3 FY25.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Earnings
Suraksha Diagnostic consolidated net profit rises 22.28% in the December 2025 quarter
Net profit of Suraksha Diagnostic rose 22.28% to Rs 7.52 crore in the quarter ended December 2025 as against Rs 6.15 crore during the previous quarter ended December 2024. Sales rose 30.55% to Rs 77.69 crore in the quarter ended December 2025 as against Rs 59.51 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales77.6959.51 31 OPM %29.8130.68 - PBDT20.6216.87 22 PBT10.068.05 25 NP7.526.15 22 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Suraksha Diagnostic to announce Quarterly Result
Suraksha Diagnostic will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Suraksha Diagnostic consolidated net profit declines 13.06% in the September 2025 quarter
Net profit of Suraksha Diagnostic declined 13.06% to Rs 8.99 crore in the quarter ended September 2025 as against Rs 10.34 crore during the previous quarter ended September 2024. Sales rose 17.95% to Rs 78.73 crore in the quarter ended September 2025 as against Rs 66.75 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales78.7366.75 18 OPM %30.6434.76 - PBDT22.1922.38 -1 PBT12.0513.63 -12 NP8.9910.34 -13 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Suraksha Diagnostic schedules board meeting
Suraksha Diagnostic will hold a meeting of the Board of Directors of the Company on 10 November 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Suraksha Diagnostic consolidated net profit rises 18.39% in the June 2025 quarter
Net profit of Suraksha Diagnostic rose 18.39% to Rs 9.40 crore in the quarter ended June 2025 as against Rs 7.94 crore during the previous quarter ended June 2024. Sales rose 19.53% to Rs 72.59 crore in the quarter ended June 2025 as against Rs 60.73 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales72.5960.73 20 OPM %32.7233.92 - PBDT21.9519.51 13 PBT12.4710.51 19 NP9.407.94 18 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Suraksha Diagnostic to conduct board meeting
Suraksha Diagnostic will hold a meeting of the Board of Directors of the Company on 8 August 2025.Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Suraksha Diagnostic to conduct AGM
Suraksha Diagnostic announced that the 20th Annual General Meeting(AGM) of the company will be held on 5 September 2025.Powered by Capital Market - Live
9 months agoCapital Market - Live
Earnings
Suraksha Diagnostic consolidated net profit rises 13.34% in the March 2025 quarter
Net profit of Suraksha Diagnostic rose 13.34% to Rs 7.39 crore in the quarter ended March 2025 as against Rs 6.52 crore during the previous quarter ended March 2024. Sales rose 17.94% to Rs 65.09 crore in the quarter ended March 2025 as against Rs 55.19 crore during the previous quarter ended March 2024. For the full year,net profit rose 34.66% to Rs 31.82 crore in the year ended March 2025 as against Rs 23.63 crore during the previous year ended March 2024. Sales rose 15.26% to Rs 252.09 crore in the year ended March 2025 as against Rs 218.71 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales65.0955.19 18 252.09218.71 15 OPM %29.4735.28 -32.2332.04 - PBDT17.9418.37 -2 76.7064.83 18 PBT9.2110.01 -8 41.4132.23 28 NP7.396.52 13 31.8223.63 35 Powered by Capital Market - Live
9 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 9.98%, vs industry avg of 13.4%
Over the last 5 years, market share decreased from 0.38% to 0.31%
Over the last 5 years, net income has grown at a yearly rate of 15.91%, vs industry avg of 42.46%